NMPA accepts clinical trial application for monkeypox vaccine
chinadaily.com.cn |
Updated: 2023-07-14 19:44
Share
Share - WeChat
The National Medical Products Administration (NMPA) has, on Thursday, officially accepted the clinical trial application for the replication-deficient monkeypox vaccine developed by China National Pharmaceutical Group Corporation (Sinopharm) Beijing Institute of Biological Products.
- Tunpu culture: A collision of civilizations
- China begins preparations for Shenzhou XXII launch
- New teaching materials to aid international Chinese language education released
- CHTF features innovative tech that coverts seawater into plastic
- Policy allowing Guangdong vehicles to travel to Hong Kong takes effect
- HK and Shenzhen jointly host the first cross-border marathon of National Games
